Does Tirzepatide Make Birth Control Less Effective? What the Label Says

Tirzepatide's label says it may, and it is the only drug in its class that says so. That warning is specific. It names a four-week window, and it comes back every time the dose goes up. Labeled contraceptive instructions are unusual on a metabolic drug. That is part of why it surprises people who have taken other drugs in this family without hearing a word about it.

Semaglutide's label carries nothing equivalent. Neither does dulaglutide's. All three slow the stomach, and only one warns about contraception.

Does the tirzepatide label actually say this?

The tirzepatide label does say this, directly, in section 8.3: "Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying."¹ That sentence appears under Females and Males of Reproductive Potential, and the same advice is repeated in section 7.2 under drug interactions.¹

Two details in that wording matter. It says may reduce, not does reduce. That is a statement about risk and not about an observed failure, and regulators choose between those two phrasings deliberately. Evidence of actual failures would have produced different wording.¹

Section 8.3 also names the mechanism, delayed gastric emptying. So the warning applies to a pill passing through a stomach, not to contraception by any other route, and the mechanism is doing the work of defining the scope.

What does the label tell patients to do?

Nothing, since the label addresses prescribers and not patients. Prescribers are told to change the method or add one. In the label's words, prescribers should "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method" or "add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation."¹

That is a label instruction to a prescriber, reproduced here because people search for it and find forum guesses instead. Anyone actually in this position needs their own prescriber, who knows which contraceptive they take and what else is going on. Nothing on this page is advice.

Several things go unmentioned. It sets no threshold dose below which the advice stops applying, names no contraceptive brands, and gives no way to tell whether an individual is affected.¹ Everybody gets the same four weeks. Labels handle a risk they cannot measure per person this way, by applying the precaution across the whole group.

What does gastric emptying have to do with pills?

Swallowed pills do not work in the stomach. Absorption happens after the pill leaves it. Your stomach holds the tablet, breaks it up and passes the contents into the small intestine. Crossing into the blood happens there.

Tirzepatide slows that handover, and the label names the slowing as the mechanism behind its contraceptive warning.¹ Pills sit in the stomach longer. Hormone reaches the intestine later and in a thinner stream, so the blood level climbs more slowly and peaks lower. None of that is a side effect in the usual sense. Slowed emptying is part of how the drug works, since food staying in the stomach longer is some of what makes people feel full, so the interaction is inseparable from the benefit. The same slowing is why an anesthesia team wants to know about these drugs before sedation.

Nothing about the pill itself changes. Same dose, same tablet, same hormone. Only the delivery schedule moves, and that is enough to shift every number in the study below. That same fact shapes the warning: patches, rings, implants, injections and IUDs never pass through a stomach, so slowing one does nothing to them.

Why four weeks, and why again at every dose increase?

Since the stomach-emptying effect is not constant, four weeks tracks its size. Each dose increase restarts the window for the same reason. Tirzepatide's label states in section 12.2 that "The delay is largest after the first dose and this effect diminishes over time."¹

So the interaction is at its strongest when exposure to the drug is new, and the body adapts with repeated dosing. Each dose escalation makes the exposure new again, so the four weeks restarts instead of being served once at the beginning. Somebody eighteen months into treatment at a stable dose is in a different position from somebody who moved up a step last week, and the label treats those two situations differently.

How much did the hormone levels actually drop?

Hormone levels dropped further than most people expect, in a single-dose study reported in section 12.3. Following a combined oral contraceptive containing "0.035 mg ethinyl estradiol and 0.25 mg norgestimate" given with a single 5 mg dose of tirzepatide, peak concentrations fell substantially: mean Cmax "was reduced by 59%, 66%, and 55%" for ethinyl estradiol, norgestimate and norelgestromin.¹

Total exposure fell far less. Mean AUC for the same three was "reduced by 20%, 21%, and 23%," and the time to peak was pushed back by "2.5 to 4.5 hours."¹

Two features of that pattern matter. All three components moved in the same direction by similar amounts. That pattern points at the delivery of the pill and not at anything specific to one hormone. And the study gave tirzepatide once, as a single dose, so the figures describe the first exposure and not what happens to somebody months into treatment at a steady dose.

Why is the peak drop so much bigger than the total drop?

Peak concentration drops further because the stomach controls the rate of absorption and not the amount. Delayed emptying means the pill's contents arrive in the small intestine later and more slowly, so the concentration curve flattens: the peak is lower, the peak is later, and the area underneath comes out closer to normal.

Reading the risk depends on that distinction. A 59% cut to peak concentration alongside a 20% cut to total exposure describes a hormone that mostly still got in, arriving on a different schedule. Whether a flatter curve is enough to let ovulation through is the question the numbers do not answer, and the label's hedge, may reduce, reflects exactly that gap.

Does this mean the pill stops working?

No study on the label measured whether the pill stops working. Pharmacokinetic work measures hormone concentrations in blood, and a concentration is a proxy. No figure in the label reports pregnancies, ovulation rates or contraceptive failures with and without tirzepatide.¹

Treating a concentration change as a failure rate overstates what was measured. Treating the absence of a failure rate as reassurance understates the warning, since the manufacturer wrote a four-week barrier instruction into the label on the strength of the concentration data alone. Between those two readings is where the label itself sits.

That omission matters, because oral contraception already fails sometimes with no drug interaction involved, through missed pills and ordinary variation between people. A question about tirzepatide is really a question about whether it moves that existing rate, and by how much. Nothing on the label speaks to either half of it, and no amount of reading the concentration figures will produce an answer.

Does semaglutide carry the same warning?

Semaglutide carries no such warning. Contraception does not appear on its label at all. Section 7 covers oral medications in general terms. The drug "causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications," the label says, and then reports that in trials "semaglutide did not affect the absorption of orally administered medications."²

Then comes an instruction to watch instead of act: "Nonetheless, monitor the effects of oral medications concomitantly administered with WEGOVY."² An oral contraceptive was among the medications assessed, named in section 12.3 as ethinylestradiol and levonorgestrel, and the label reports that "No clinically relevant drug-drug interactions with semaglutide were observed based on the evaluated medications."²

Does dulaglutide?

Dulaglutide carries nothing on contraception. Section 7.1 of its label says the drug "has the potential to reduce the rate of absorption of concomitantly administered oral medications," and section 12.3 reports that the 1.5 mg dose did not affect the oral medications tested to any clinically relevant degree.³

Clinically relevant is a judgment and not a measurement. A change can be real, reproducible and still fall below the threshold a sponsor and a regulator agree calls for action, and where that threshold sits is not published alongside the phrase. Dose matters too, since 1.5 mg is not the top of the dulaglutide range.

Three labels describe one mechanism and carry one warning between them. Reading that as proof that tirzepatide is uniquely dangerous to contraception goes further than the documents support. Reading the other two as cleared goes just as far in the other direction. The three differ in more than this one line, and a side-by-side of semaglutide, tirzepatide and retatrutide covers the rest.

Why would labels in the same class disagree?

Labels in the same class disagree because the studies behind them were designed differently, and the documents show it. The tirzepatide contraceptive study used a single 5 mg dose, the first dose a participant received.¹ The semaglutide assessment looked at the oral contraceptive "at steady state," after repeated dosing.²

Set that against tirzepatide's own statement that the gastric delay "is largest after the first dose and this effect diminishes over time," and the two studies look at opposite ends of the same curve.¹ One measured the interaction at its maximum. The other measured it after the effect had faded. Neither design is wrong, and the results are not comparable.

What follows is narrower than it looks. The absence of a warning on the semaglutide label is not evidence that semaglutide leaves oral contraception alone at the moment of a first dose or a dose increase, because nothing in that label reports testing at that moment.

Does the warning cover the patch, the ring, an IUD or an implant?

The warning points away from the patch, the ring, an IUD and an implant, advising a switch "to a non-oral contraceptive method" as one of the two options.¹ A mechanism that works by slowing the stomach has nothing to act on when the hormone never passes through one. The second option is adding a barrier method. In practice that means condoms for those four weeks, kept alongside the pill instead of replacing it.

That logic is the label's own, since a non-oral method would be a strange thing to recommend if the concern reached beyond swallowed contraceptives. Non-oral methods go unnamed, and that is a conversation for a prescriber.

What the label leaves unstated is as useful as what it says. It names no specific alternative, sets no preference between switching and adding a barrier, and offers no guidance for somebody who cannot easily do either. A prescriber fills those gaps with knowledge of the individual, and the label was written to them for that reason.

What about Zepbound, the same drug under another name?

Zepbound holds the same drug. Searching the openFDA label records for this page returned no entry under that brand. Nothing here should be read as a statement about that product's labeling. It may be worded identically or not at all the same, and the underlying molecule and the mechanism do not change with the brand name. A labeled instruction belongs to a specific document, and the document for that brand was not read.

Brands of one molecule can carry different labeling for ordinary reasons. Each goes through its own application, with its own studies attached and its own approved indications, and the sections are written at different times. Two labels for the same drug agreeing is the common case and not a rule, so the only safe statement is the one made here: this page reports what one document says.

What should somebody taking both actually do?

Anybody taking both should raise it with their prescriber, since these documents are written to prescribers and not to patients. What this page can do is set out what the document says so the conversation starts from the right place.

Three details shape the answer. The first is the contraceptive itself, since the study used a combined pill and progestin-only formulations were not tested. Second comes where somebody sits in their dose escalation, since the label attaches its four-week windows to starting and to each increase. Third is whether a non-oral method is available, because the label offers that as its first of two routes.

Two circumstances sit outside that list. A combined pill is often prescribed for cycle control and not for contraception, so a warning addressed to birth control can read as somebody else's problem, and the absorption change does not care why the prescription was written. The same label also states the drug may restore fertility, since weight loss can restart ovulation in people who were not ovulating before. Our guide to peptides, fertility and pregnancy covers that second half.

People search this question because the answer is hard to find. Pharmacy leaflets vary, forums guess, and the label text is buried in a document most people never see. Reading the actual sentences is not the same as being advised. Anybody relying on contraception needs the advice too.

What has not been measured?

Pregnancy outcomes were never measured. No figure on any of them reports whether anyone taking tirzepatide and an oral contraceptive became pregnant at a higher rate than anyone else.¹

The contraceptive study also used one formulation at one dose, 0.035 mg ethinyl estradiol with 0.25 mg norgestimate, and one tirzepatide dose given once.¹ Progestin-only pills, different estrogen doses and the effect of a dose escalation in somebody already established on treatment were not part of it. Readers on a different pill are extrapolating. So are readers at a different point in their escalation.

What would settle it?

Nothing settles it short of an outcome study, and nobody has published one. The question people actually have is whether contraception fails more often on this drug, and that needs pregnancy rates in people taking both, not hormone curves.

Until that exists, the label's four-week instruction rests on a single-dose concentration study, and the absence of similar instructions on the other labels rests on studies run at a different point in the dosing cycle. Both of those are thinner foundations than the confident writing on this subject suggests.

Describing the useful study is easy and running it is expensive. It would follow people taking an oral contraceptive alongside each of these drugs, through initiation and through dose increases, and report pregnancies. Absent that, the labels are reporting hormone curves and everybody downstream is interpreting them, this page included.

Common questions

Does tirzepatide make birth control less effective?

How long do I need a backup method?

Why does the window restart at every dose increase?

How much do hormone levels actually fall?

Why is the peak reduced so much more than the total?

Does semaglutide affect birth control?

Does Ozempic or Wegovy need a backup method?

Does Mounjaro affect the patch, ring or IUD?

Is this a class effect for all GLP-1 drugs?

Has anyone shown contraception actually failing on tirzepatide?

Does the warning apply to progestin-only pills?

What if I have been on a stable dose for a year?

Does food or timing change this?

Why does one drug get a warning when the others do not?

Sources

1. Mounjaro (tirzepatide) injection, US prescribing information, sections 7.2, 8.3, 12.2 and 12.3. Read at source via the openFDA drug label API, https://api.fda.gov/drug/label.json. The contraceptive efficacy statement, the advice to switch to a non-oral method or add a barrier method for 4 weeks after initiation and after each dose escalation, the statement that the gastric emptying delay is largest after the first dose, and the single-dose combined oral contraceptive study reporting Cmax reductions of 59%, 66% and 55%, AUC reductions of 20%, 21% and 23%, and a tmax delay of 2.5 to 4.5 hours. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15
2. Wegovy (semaglutide) injection, US prescribing information, sections 7 and 12.3. Read at source via the openFDA drug label API, https://api.fda.gov/drug/label.json. The general oral medication interaction wording, the statement that semaglutide did not affect the absorption of orally administered medications, the instruction to monitor, and the assessment of an oral contraceptive containing ethinylestradiol and levonorgestrel at steady state. The label carries no contraceptive-specific advice. ↩1 ↩2 ↩3 ↩4
3. Trulicity (dulaglutide) injection, US prescribing information, sections 7.1 and 12.3. Read at source via the openFDA drug label API, https://api.fda.gov/drug/label.json. The statement that the drug has the potential to reduce the rate of absorption of concomitantly administered oral medications, and that the 1.5 mg dose did not affect the oral medications tested to a clinically relevant degree. The label carries no contraceptive-specific advice. ↩1